Navigation Links
Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
Date:2/7/2013

hin in the participants' muscles the latter results obtained through muscle biopsies at several times during study. Of particular interest to the research teams are the residual effects of the drug several weeks after the injection series is completed.

Although McDonald says it is too early to draw conclusions from the current clinical trial, he suggests there is reason to be optimistic based on animal studies and evidence from another clinical trial in Europe. In that trial, patients and study investigators knew which patients were actually taking the experimental drug, meaning it was an "open" study. The current U.S. study is more rigorous because doctors and families are "blinded" about which drug regimen each participant has -- either one of two dosages of the drug or a placebo -- until the end of the study.

According to McDonald, the antisense oligonucleotide-mediated genetic therapy approach is particularly exciting because of its potential applications to most other variants of Duchenne muscular dystrophy and other genetic diseases. Although the current experimental therapy specifically addresses mutations in only one particular region of the gene, the same therapeutic concept can be applied to many others.

"If successful, this approach can be developed into specific gene therapy that represents truly personalized medicine," said McDonald. "Covering a mutation to restore a normal genetic open reading frame for protein synthesis can be a powerful approach for a variety of genetic diseases."

Standardizing the drug as a therapy for Duchenne patients still requires approval by the U.S. Food and Drug Administration. Investigators say the therapy could be similar to insulin injections for diabetes. But rather than daily injections, the Duchenne treatment might only involve weekly shots, which youngsters could learn to administer on their own.

Now that the clinical trial is closed at UC Davis to new enrollees, McDonald
'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Experimental drug combination selectively destroys lymphoma cells
2. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
3. Compound stimulates tumor-fighting protein in cancer therapy
4. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
5. Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy
6. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
7. BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection
8. Canada launches first gene therapy trial for Fabry disease
9. New way to kill lymphoma without chemotherapy
10. Gene therapy reprograms scar tissue in damaged hearts into healthy heart muscle
11. New whole plant therapy shows promise as an effective and economical treatment for malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... A University of California, Davis, microbiologist and a professional ... microbes to the International Space Station and study their ... Nov. 29 as winners of the International Space Station ... The team is led by Professor Jonathan Eisen ...
... 7. Dezember 2012 /PRNewswire/ -- Integrated Biometrics, LLC ... neuesten Fingerabdrucktechnologie einen weiteren technologischen Durchbruch bekannt. ... Produkt unter Verwendung der LES-Technologie (Light Emitting ... Film Transistor, TFT) her. Die LES-Technologie verwendet ...
... new plant-parasitic nematode worm ( Meloidoderita salina ) ... Michel Bay (MSMB) in France, where its abbey is a ... soil and is derived from the Latin word ,sal, or ... open source scientific journal ZooKeys . ...
Cached Biology News:Cheering microbes into space 2Integrated Biometrics stellt Sherlock vor - die weltweit leichtesten, dünnsten und kleinsten Appendix F Mobile ID-Fingerabdrucksensoren 2A pattern given by nature 2
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
(Date:5/20/2015)... 2015  Select Medical Corporation ("Select") (NYSE: ... granted early termination of the waiting period under ... as amended, applicable to the acquisition of Concentra ... venture that Select has created with Welsh, Carson, ... announced, MJ Acquisition Corporation has signed a definitive ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Nanotechnologies, Inc. ("Shrink") (OTC Markets: INKN), an innovative high ... binding letter of intent to acquire 100% of Hawaii-based ... with global distribution for its award-winning suites of life ... Shrink will exchange 25,750,000 shares of ...
... 11, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... and biopharmaceutical industries, today announced that its President ... at the Advanced Biofuels Leadership Conference taking place ...
... advancements of our electronic age rests on our ability ... to point B, through circuitry. Doing so requires particular ... solar cells, and that task falls to semiconductors. ... schools of Engineering and Applied Science and Arts and ...
Cached Biology Technology:Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: